

Most of the research in our laboratory has used coronaviruses as models to study the genetics of RNA virus transcription, replication, persistence, and cross species transmission. We have also been using alphavirus vaccine vectors to develop novel candidate vaccines against caliciviruses. Specific areas of interest include:

E-Mail

✉ rbaric@email.unc.edu

1. Coronavirus Reverse Genetics and vaccine development.

We have developed infectious cDNAs from two coronaviruses. Specific applications include: a) studying critical cis and trans acting factors that regulate coronavirus subgenomic mRNA synthesis and replication, b) rearranging the coronavirus gene order to study genome evolution and function in coronavirus transcription and replication, c) identification of the minimal coronavirus genome, d) development of coronavirus replicon RNAs and coronavirus replicon particles for vaccine development, e) expression of heterologous genes from coronavirus vaccine vectors for swine and other important species.

In this work a possible procedure to generate chimeric viruses is described:

Manipulation of the Coronavirus Genome Using Targeted RNA Recombination with Interspecies Chimeric Coronaviruses

Cornelis A.M. de Haan, Bert Jan Haijema, Paul S. Masters, and Peter J.M. Rottier

1999: First Chimeric Coronavirus
Crossing the Host Cell Species Barrier

Another interesting information:

Title: Methods and compositions for chimeric coronavirus spike proteins United States Patent 9884895 Inventors: Baric, Ralph

(Haw River, NC, US) Agnihothram, Sudhakar (Ellicott City, MD, US) Yount, Boyd (Hillsborough, NC, US) Publication Date:

02/06/2018

Assignee:

The University of North Carolina at Chapel Hill (Chapel Hill, NC, US)

2. Norwalk like virus (Calicivirus) vaccine development.

We are using the alphavirus, Venezuelan equine encephalitis virus (VEE), as a vaccine vector for the Norwalk like viruses. Our research encompasses: a) expression of Norwalk and SnowMountain virus capsid proteins from VEE, b) biochemical and immunologic characterization of these recombinant proteins, c) vaccine testing in mice, and d) use a human challenge model to identify immunologic responses associated with protection from NLV reinfection.

3. RNA virus transcription, replication and recombination.

Our laboratory has had a longstanding interest in using genetic approaches to study coronavirus transcription, replication and RNA recombination.

4. RNA virus persistence, cross species transmission and virus-host coevolution.

Our laboratory has studied the mechanism for coronavirus persistence in vitro.

This occurs by virus selection for resistant host cells that down regulate the expression of the host receptor needed for coronavirus docking and entry. The emergence of these resistant host cells subsequently selects for the coevolution of virus variants that recognize new receptors for docking and entry. Virus variants evolve with expanded host range through recognition of phylogenetic homologues of the normal coronavirus receptor. Consequently, we are studying the mechanisms of RNA virus-host cell coevolution and virus receptor interactions that regulate virus host range expansion.

Publications

Denison MR, Graham RL, Donaldson EF, Eckerle LD, Baric RS (2011).

Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. *RNA Biol.* 8(2):270-9.

Sheahan T, Whitmore A, Long K, Ferris M, Rockx B, Funkhouser W, Donaldson E,

Gralinski L, Collier M, Heise M, Davis N, Johnston R, Baric RS (2011). Successful

vaccination strategies that protect aged mice from lethal challenge from influenza

virus and heterologous severe acute respiratory syndrome coronavirus. *J Virol.*

85(1):217-30.

Rockx B, Donaldson E, Frieman M, Sheahan T, Corti D, Lanzavecchia A, Baric RS

(2010). Escape from human monoclonal antibody neutralization affects in vitro

and in vivo fitness of severe acute respiratory syndrome coronavirus. *J Infect Dis.*

201(6):946-55.

Frieman M, Ratia K, Johnston RE, Mesecar AD, Baric RS (2009). Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. *J Virol.* 83(13):6689-705.

Donaldson EF, Sims AC, Baric RS (2008). Systematic assembly and genetic manipulation of the mouse hepatitis virus A59 genome. *Methods Mol Biol.* 454:293-315.

Donaldson EF, Yount B, Sims AC, Burkett S, Pickles RJ, Baric RS (2008). Systematic assembly of a full-length infectious clone of human coronavirus NL63. *J Virol.* 82(23):11948-57.

Sheahan T, Rockx B, Donaldson E, Corti D, Baric R (2008). Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus. *J Virol.* 82(17):8721-32.

Sheahan T, Rockx B, Donaldson E, Sims A, Pickles R, Corti D, Baric R (2008).

Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium.

J Virol. 82(5):2274-85.

Enjuanes L, Dediego ML, Alvarez E, Deming D, Sheahan T, Baric R (2008). Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 133(1):45-62.

Deming DJ, Graham RL, Denison MR, Baric RS (2007). Processing of open reading frame 1a replicase proteins nsp7 to nsp10 in murine hepatitis virus strain A59 replication. J Virol. 81(19):10280-91.

Rockx B, Sheahan T, Donaldson E, Harkema J, Sims A, Heise M, Pickles R, Cameron M, Kelvin D, Baric R (2007). Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice. J Virol. 81(14):7410-23.

Sheahan T, Deming D, Donaldson E, Pickles R, Baric R (2006). Resurrection of an "extinct" SARS-CoV isolate GD03 from late 2003. Adv Exp Med Biol. 581:547-50.

McRoy WC, Baric RS (2006). Spike gene determinants of mouse hepatitis virus host range expansion. Adv Exp Med Biol. 581:301-4.

Frieman MB, Yount B, Sims AC, Deming DJ, Morrison TE, Sparks J, Denison M, Heise M, Baric RS (2006). SARS coronavirus accessory ORFs encode luxury functions. Adv Exp Med Biol. 581:149-52.

Pekosz A, Schaecher SR, Diamond MS, Fremont DH, Sims AC, Baric RS (2006). Structure, expression, and intracellular localization of the SARS-CoV accessory proteins 7a and 7b. Adv Exp Med Biol. 581:115-20.

Yount B, Roberts RS, Lindesmith L, Baric RS (2006). Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome. Proc Natl Acad Sci U S A. 103(33):12546-51.